These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15667234)

  • 1. Health plan budget impact analysis for pimecrolimus.
    Chang J; Sung J
    J Manag Care Pharm; 2005; 11(1):66-73. PubMed ID: 15667234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
    Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M
    J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age.
    Ellis CN; Kahler KH; Grueger J; Chang J
    Am J Clin Dermatol; 2006; 7(2):133-9. PubMed ID: 16605293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
    Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
    J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus.
    Weinberg JM
    J Manag Care Pharm; 2005; 11(1):56-64. PubMed ID: 15667233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact of tegaserod on a managed care organization formulary.
    Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
    Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis.
    Taneja C; Antaya RJ; Berger A; Marshall TS; Seifeldin R; Oster G
    J Drugs Dermatol; 2010 Apr; 9(4):372-6. PubMed ID: 20514795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
    Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
    Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data.
    Meyer CM; Phipps R; Cooper D; Wright A
    J Manag Care Pharm; 2003; 9(2):168-74. PubMed ID: 14613346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.